Migsun (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium inhibits cyclo‑oxygenase enzymes COX‑1 and COX‑2, reducing prostaglandin synthesis and inflammation that contribute to pain. Sumatriptan succinate selectively activates 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings, causing vasoconstriction and blocking release of pro‑inflammatory neuropeptides. Together they address both vascular and inflammatory components of a migraine attack.

The specific dose and dosing schedule of Migsun are determined by the prescribing healthcare professional based on the individual’s clinical condition, severity of migraine, and any concomitant medications. Patients should follow the prescriber’s instructions and the product labeling, and should not adjust the dose without medical advice.

Safety of Migsun during pregnancy or lactation has not been fully established. Naproxen sodium is generally avoided in the third trimester because of potential fetal cardiovascular effects, and sumatriptan is classified as pregnancy category C in many regions. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician before using this medication.

To place an order, visit the product page for Migsun on the GNH India website (gnhindia.com), enter the required quantity, and submit the enquiry form. GNH India supplies hospitals, pharmacies, and procurement teams worldwide; the sales team will verify institutional credentials, then provide pricing, availability, shipping details (including any temperature‑controlled logistics), and assist with import documentation.

Compared with single‑agent triptans, Migsun adds an NSAID component, which can enhance pain relief, reduce the need for additional analgesics, and potentially lower the risk of recurrence. Relative to NSAID‑only therapy, the sumatriptan component provides targeted vasoconstriction, addressing the vascular component of migraine. Clinical studies suggest the combination may achieve faster and more sustained headache relief than either component alone.

Migsun tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date printed on the label. No special refrigeration is required.

Migsun is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not crushed, chewed, or broken, unless otherwise directed by a healthcare professional. It is typically taken at the onset of a migraine attack, and patients should follow the dosing instructions provided by their prescriber.

The most serious risks include cardiovascular events such as myocardial infarction or stroke, particularly in patients with pre‑existing heart disease, and serotonin syndrome when combined with other serotonergic agents. Severe allergic reactions, including anaphylaxis, can also occur. Patients should seek immediate medical attention if they experience chest pain, rapid heartbeat, severe dizziness, or signs of an allergic reaction.

Migsun is contraindicated in individuals with known hypersensitivity to naproxen, sumatriptan, or any component of the formulation. It should not be used by patients with uncontrolled hypertension, recent ischemic heart disease, severe hepatic or renal impairment, or those taking monoamine oxidase inhibitors within the past 14 days. Pregnant women in the third trimester and patients with certain vascular disorders should also avoid this medication.